Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: Recommendations of an expert panel

Leukemia and Lymphoma

Volumn 52, Issue 12, 2011, Pages 2237-2253

  Stock, Wendy ^a   Douer, Dan ^b   Deangelo, Daniel J ^c   Arellano, Martha ^d   Advani, Anjali ^e   Damon, Lloyd ^f   Kovacsovics, Tibor ^g   Litzow, Mark ^h   Rytting, Michael ⁱ   Borthakur, Gautam ⁱ   Bleyer, Archie ^g,j,k  

^a UNIVERSITY OF CHICAGO   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c HARVARD UNIVERSITY   (United States)

^d EMORY UNIVERSITY   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^h MAYO CLINIC   (United States)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^j St Charles Health System   (United States)

^k UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

more..

Author keywords

Adults; Asparaginase; Guidelines; Pegasparaginase; Toxicities

Indexed keywords

4 AMINOPHENOL; ADRENALIN; ANTHRACYCLINE; ANTICOAGULANT AGENT; ANTIHISTAMINIC AGENT; ASPARAGINASE; ASPARAGINASE MACROGOL; BLOOD CLOTTING FACTOR 8; DAUNORUBICIN; DEXAMETHASONE; DIPHENHYDRAMINE; FIBRINOGEN; FRESH FROZEN PLASMA; GEMFIBROZIL; GLUCOSE; HYDROCORTISONE; IMIPENEM; INFUSION FLUID; INSULIN; LACTULOSE; LOW MOLECULAR WEIGHT HEPARIN; NAFAMSTAT MESILATE; OCTREOTIDE; OXYGEN; PARACETAMOL; PREDNISONE; STEROID; VINCA ALKALOID; VINCRISTINE;

ABDOMINAL PAIN; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; ALBUMIN BLOOD LEVEL; ANGIONEUROTIC EDEMA; ANTIBIOTIC THERAPY; ANTICOAGULANT THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; BRAIN DISEASE; BRAIN ISCHEMIA; BULIMIA; CANCER SURVIVAL; COMA; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CRYOPRECIPITATE; DIET; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPISTAXIS; ERWINIA; ESCHERICHIA COLI; EXERCISE; FAMILY HISTORY; FATIGUE; FIBRINOGEN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSURIA; GLYCEMIC CONTROL; HUMAN; HYPERAMMONEMIA; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; HYPERTRIGLYCERIDEMIA; HYPOFIBRINOGEMIA; HYPOTENSION; INCIDENCE; INSULIN TREATMENT; INTERNATIONAL NORMALIZED RATIO; INTRAVENOUS CATHETER; KETOACIDOSIS; LARYNX SPASM; LEUKOENCEPHALOPATHY; LIVER TOXICITY; LOW DRUG DOSE; METABOLIC DISORDER; NAUSEA; NEUROPATHY; NEUROTOXICITY; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL CONTRACEPTION; PANCREATITIS; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; POLYDIPSIA; POLYURIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; PROTHROMBIN TIME; SEIZURE; SIDE EFFECT; SKIN BRUISING; SOMNOLENCE; STEROID THERAPY; STROKE; SURVIVAL TIME; THROMBOEMBOLISM; THROMBOSIS; TREATMENT DURATION; TREATMENT WITHDRAWAL; UREMIA; URTICARIA; VOMITING; WHEEZING;

ADOLESCENT; ADULT; AGE FACTORS; ANTINEOPLASTIC AGENTS; ASPARAGINASE; HUMANS; POLYETHYLENE GLYCOLS; PRACTICE GUIDELINES AS TOPIC; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 81255127708     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.596963     Document Type: Article

References (125)

1. Stock W, La M, Sanford B, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood 2008;112:1646-1654.
2. Boissel N, Auclerc MF, Lheritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 2003;21:774-780. (Pubitemid 46606434)
3. de Bont JM, Holt B, Dekker AW, van der Does-van den Berg A, Sonneveld P, Pieters R. Signif cant dif erence in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia 2004;18: 2032-2035. (Pubitemid 40028431)
4. de Bont JM, van der Holt B, Dekker AW, van der Does-van den Berg A, Sonneveld P, Pieters R. Adolescents with acute lymphatic leukaemia achieve signif cantly better results when treated fol lowing Dutch paediatric oncology protocols than with adult protocols. Ned Tijdschr Geneeskd 2005;149:400-406. (Pubitemid 40310837)
5. Schroeder H, Kjeldahl M, Boeson AM, et al. Prognosis of ALL in 10-20 year old patients in Denmark 1992-2001. Pediatr Blood Cancer 2005;45:578 Abstract.
6. Testi A. Dif erence in outcome of adolescents (14-17 years) with acute lymphoblastic leukaemia (ALL) enrolled in the Italian pediatric (AIEOP) an adult (GIMEMA) multicenter treatment protocols. J Clin Oncol 2006;24(18 Suppl.): Abstract 9024.
7. Ramanujachar R, Richards S, Hann I, et al. Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials. Pediatr Blood Cancer 2007;48:254-261. (Pubitemid 46238513)
8. Ramanujachar R, Richards S, Hann I, Webb D. Adolescents with acute lymphoblastic leukaemia: emerging from the shadow of paediatric and adult treatment protocols. Pediatr Blood Cancer 2006;43:748-756. (Pubitemid 44476750)
9. Barry E, DeAngelo DJ, Neuberg D, et al. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. J Clin Oncol 2007;25:813-819. (Pubitemid 350002881)
10. Sallan SE, Gelber RD, Kimball V, Donnelly M, Cohen HJ. More is better! Update of Dana-Farber Cancer Institute/Children's Hospital childhood acute lymphoblastic leukemia trials. Haematol Blood Transfus 1990;33:459-466.
11. Amylon MD, Shuster J, Pullen J. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Blood 2000;96:335-342.
12. Raetz EA, Salzer WL. Tolerability and ef cacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia. J Pediatr Hemat Oncol 2010;32:554-563.
13. Asselin BL, Kreissman S, Coppola DJ, Bernal SD, Leavitt PR, Gelber RD, Sallan SE, Cohen HJ. Prognostic signif cance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 1999;21(1):6-12. (Pubitemid 29131987)
14. Silverman L, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia:results of Dana-Farber consortium protocol 91-01. Blood 2001:97;1211-1218. (Pubitemid 32183741)
15. Nachman JB, La MK, Hunger SP, et al. Young adults with acute lymphoblastic leukemia have an excellent outcome with chemo therapy alone and benef t from intensive postinduction treatment: a report from the Children's Oncology Group. J Clin Oncol 2009;27:5189-5194.
16. Wetzler M, Sanford BL, Kurtzburg J, et al. effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. Blood 2007;109:4164-4167. (Pubitemid 46743378)
17. Huguet F, Leguay T, Rafoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol 2009;27:911-918.
18. Goekbuget N, Baumann A, Beck J, et al. PEG-asparaginase in adult acute lymphoblastic leukemia: efficacy and feasibility analysis with increasing dose levels. Blood 2008;112(Suppl. 1): Abstract 302.
19. DeAngelo DJ. Te treatment of adolescents and young adults with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2005:123-130.
20. DeAngelo DJ, Stone RM. New agents for the treatment of patients with acute lymphoblastic leukemia. Curr Hematol Malig Rep 2008;3:135-143. (Pubitemid 352008928)
21. Aguayo A, Cortes J, Thomas D, et al. Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia. Cancer 1999;86:1203-1209. (Pubitemid 29447003)
22. Rosen O, Muller HJ, Gokbuget N, et al. Pegylated asparaginase in combination with high-dose methotrexate for consolidation in adult acute lymphoblastic leukaemia in f rst remission: a pilot study. Br J Haematol 2003;123:836-841. (Pubitemid 37533295)
23. Storring J, Minden M, Kao S, et al. Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modif ed paediatric regimen. Br J Haematol 2009;146:76-85.
24. Oettgen H F, Stephenson PA, Schwartz MK, et al. Toxicity of E.coli l-asparaginase in man. Cancer 1970;25:253-278.
25. Dinndorf PA, Gootenberg J, Cohen MH, Keegan P, Pazdur R. FDA drug approval summary: pegaspargase (Oncaspar) for the f rst-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist 2007;12:991-998. (Pubitemid 47359142)
26. Graham ML. Pegaspargase: a review of clinical studies. Adv Drug Deliv Rev 2003;55:1293-1302. (Pubitemid 37464563)
27. Duval M, Suciu S, Ferster A, et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer Children's Leukemia Group phase 3 trial. Blood 2002;99:2734-2739. (Pubitemid 34525359)
28. Ettinger LJ, Kurtzberg J, Voute PA, et al. An open-label, multicenter study of polyethylene glycol-L-asparaginase of the treatment of acute lymphoblastic leukemia. Cancer 1995;75:1176-1181.
29. Sallan SE. Myths and lessons from the adult/pediatric interface in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2006:128-132.
30. Advani A, Earl M, Douer D, Rytting M, Bleyer A. Toxicities of intravenous pegasparaginase (Oncaspar) in adults with acute lymphoblastic leukemia. Blood 2007;110(Suppl. 1): Abstract 2811.
31. Rytting M, Earl M, Douer D, Muriera B, Advani A, Bleyer A. Toxicities in adults with acute lymphoblastic leukemia treated with regimens using pegasparaginase. Blood 2008;112(Suppl. 1): Abstract 1924.
32. Earl M. Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia. Clin Adv Hemat Oncol 2009;7:600-606.
33. Rytting M. Peg-asparaginase for acute lymphoblastic leukemia. Expert Opin Biol Ter 2010;27:1-7.
34. Seibel NL, Steinherz PG, Sather HN, et al. Early postinduction intensif cation therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2008;111:2548-2555.
35. Muller HJ, Loning L, Horn A, et al. Pegylated asparaginase (OncasparTM) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols. Br J Haematol 2000;110:379-384. (Pubitemid 30646864)
36. Larson RA, Fretzin MH, Dodge RK, Schifer CA. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Leukemia 1998;12:660-665. (Pubitemid 28220817)
37. Avramis V, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 2002;99:1986-1994. (Pubitemid 34525479)
38. Armstrong JK, Hempel G, Koling S, et al. Antibody against polyethylene glycol adversely af ects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 2007;110:103-111. (Pubitemid 46986423)
39. Panetta JC, Gajjar A, Hijiya N, et al. Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia. Clin Pharmacol Ter 2009;86:651-658.
40. Strullu M, Corradini N, Audrain M, et al. Silent hypersensitivity to Escherichia coli asparaginase in children with acute lymphoblastic leukemia. Leuk Lymphoma 2010;51:1464-1472.
41. Zalewska-Szewczyk B, Andrzejewski W, M ł ynarski W, Jedrychowska-Dań ska K, Witas H, Bodalski J. Te anti-asparagines antibodies correlate with L-asparagines activity and may af ect clinical outcome of childhood acute lymphoblastic leukemia. Leuk Lymphoma 2007;48:931-936. (Pubitemid 47161565)
42. Cheung NK, Chau IY, Coccia PF. Antibody response to Escherichia coli L-asparaginase. Prognostic signif cance and clinical utility of antibody measurement. Am J Pediatr Hematol Oncol 1986;8: 99-104. (Pubitemid 16092149)
43. Vieira Pinheiro JP, Muller HJ, Schwabe D, et al. Drug monitoring of low-dose pegylated asparaginase (OncasparTM) in children with relapse acute lymphoblastic leukaemia. Br J Haematol 2001; 113:115-119. (Pubitemid 32423311)
44. Douer D, Watkins K, Nathwani N, Levine AM, Tiwari PN, Avramis VI. Te pharmacokinetics, safety and lack of antibody production from multiple doses of intravenous pegylated asparaginase in adults with newly diagnosed acute lymphoblastic leukemia. Blood 2006;108(Suppl. 1): Abstract 1873.
45. Douer D, Watkins K, Mark L, et al. Multiple doses of intravenous pegylated asparaginase with a'pediatric-like'protocol in adults with newly diagnosed acute lymphoblastic leukemia (ALL): toxicity, clinical outcome and low rate of anti asparaginase antibody formation. Blood 2009;114(Suppl. 1): Abstract 3082.
46. Avramis V, Panosyan EH. Pharmacokinetic/pharmacodynamics relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin Pharmacokin 2005;44:367-393. (Pubitemid 40663683)
47. Yang L, Panetta JC, Cai X, et al. Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. J Clin Oncol 2008;26:1932-1939.
48. McNeer JL, Nachman JB. Te optimal use of steroids in paediatric acute lymphoblastic leukaemia: no easy answers. Br J Haematol 2010;149:638-652.
49. Knoderer HM, Robarge J, Flockhart DA. Predicting asparaginase-associated pancreatitis. Pediatr Blood Cancer 2007;49:634-639. (Pubitemid 350194426)
50. Top PC, Tissing WJ, Kuiper JW, Pieters R, van Eijck CH. L-asparaginase induced severe acute necrotizing pancreatitis successfully treated with percutaneous drainage. Pediatr Blood Cancer 2005;44:95-97. (Pubitemid 39602574)
51. Kearney S, Dahlberg S, Levy D, Voss SD, Sallan SE, Silverman LB. Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis. Pediatr Blood Cancer 2009;53:162-167.
52. Hawkins DS, Park JR, Thomson BG, et al. Asparaginase pha-rmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lym-phoblastic leukemia. Clin Cancer Res 2004;10:5335-5341. (Pubitemid 39100468)
53. Abshire T, Pollock B, Billett A, et al. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 2000;96:1709-1715. (Pubitemid 30661053)
54. Rizzari C, Citterio M, Zucchetti M, et al. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia. Haematologica 2006;91:24-31. (Pubitemid 43235382)
55. Alvarez OA, Zimmerman G. Pegaspargase-induced pancreatitis. Med Pediatr Oncol 2000;34:200-205. (Pubitemid 30132143)
56. Land VJ, Sutow WW, Fernbach DJ, et al. Toxicity of l-asparaginase in children with advanced leukemia. Cancer 1972;30:339-347.
57. Garrington T, Bensard D, Ingram JD, Silliman CC. Successful management with octreotide of a child with L-asparaginase induced hemorrhagic pancreatitis. Med Pediatr Oncol 1998;30;106-109. (Pubitemid 128765925)
58. Suzuki M, Takara O, Sakaguchi S, Fujimara J, Saito M, Shimizu T. Retherapy using L-asparaginase with octreotide in a patient recovering from L-asparginase-induced pancreastitis. Exp Hematol 2008;36: 253-254. (Pubitemid 351221172)
59. Paran H, Neufeld D, Mayo A, et al. Preliminary report of a prospective randomized study of octreotide in the treatment of severe acute pancreatitis. J Am Coll Surg 1995;181:121-124.
60. Tauber MT, Harris AG, Rochiccioli P. Clinical use of the long acting somatostatin analogue octreotide in pediatrics. Eur J Pediatr 1994:153:304-310. (Pubitemid 24137443)
61. Morimoto A, Imamura T, Ishii R, et al. Successful management of severe L-asparaginase-associated pancreatitis by continuous regional arterial infusion of protease inhibitor and antibiotic. Cancer 2008;113:1362-1369.
62. Imaizumi H, Kida M, Nishimaki H, et al. Ef cacy of continuous regional arterial infusion of a protease inhibitor and antibiotic for severe acute pancreatitis in patients admitted to an intensive care unit. Pancreas 2004;28:369-373. (Pubitemid 38509739)
63. Taylor CW, Dorr RT, Fanta P, et al. A phase I and pharmacodynamics evaluation of polyethylene glycol-conjugated L-asparaginase in patients with advanced solid tumors. Cancer Chemother Pharmacol 2001;47:83-88. (Pubitemid 32664518)
64. Whitecar JP Jr, Bodey GP, Hill CS Jr, Samaan NA. effect of L-asparaginase on carbohydrate metabolism. Metabolism 1970; 19:581-586.
65. Gailani S, Nussbaum A, Onuma T, Freeman A. Diabetes in patients treated with asparaginase. Clin Pharmacol Ter 1971;12: 487-490.
66. Carpentieri U, Balch MT. Hyperglycemia associated with the therapeutic use of L-asparaginase: possible role of insulin receptors. J Pediatr 1978;93:775-778. (Pubitemid 8397584)
67. Khan A, Adachi M, Hill JM. Potentiation of diabetogenic effect of L-asparaginase by prednisolone. Horm Metab Res 1970;2: 275-276.
68. Lowas S, Marks D, Malempati S. Prevalence of transient hyper-glycemia during induction chemotherapy for pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer 2009;52:814-818.
69. Salzer WL, Devidas M, Schuster JJ, et al. Intensified PEG-l-asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: a report from the Children's Oncology Group. J Pediatr Hematol Oncol 2007;29:369-375. (Pubitemid 46884218)
70. Douer D, Yampolsky H, Cohen LJ, et al. Pharmacodynamics and safety of intravenous pegasparaginase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood 2007;109:2744-2750. (Pubitemid 46482066)
71. Pui CH, Burghen GA, Bowman WP, Aur RJ. Risk factors for hyperglycemia in children with leukemia receiving L-asparaginase and prednisone. J Pediatr 1981;99:46-50. (Pubitemid 11046416)
72. Howard SC, Pui CH. Endocrine complications in pediatric patients with acute lymphoblastic leukemia. Blood Rev 2002;16: 224-234.
73. Cairo MS. Adverse reactions of l-asparaginase. Am J Pediatr Hemat Oncol 1982;4:335-339. (Pubitemid 13197854)
74. Sahoo S, Hart J. Histopathologic features of l-asparaginase-induced liver disease. Semin Liver Dis 2003;23:295-299. (Pubitemid 37052454)
75. Schein PS, Rakieten N, Gordon BM, Davis RD, Rau DP. Te toxicity of Escherichia coli l-asparaginase. Cancer Res 1969;29:426-434.
76. Bodmer M, Sulz M, Stadlmann S, Droll A, Terracciano L, Krähenbühl S. Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L asparaginase. Digestion 2006;74:28-32. (Pubitemid 44835688)
77. Parsons SK, Skapek SX, Neufeld EJ, et al. Asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia. Blood 1997;89:1886-1895. (Pubitemid 27132102)
78. Haskell CA, Canellos GJ, Leventhall BJ. L-asparaginase toxicity. Cancer Res 1969;29:974-975.
79. Whitecar JP, Bodey GP, Harris JE, et al. L-asparaginase. N Engl J Med 1970;282:732-734.
80. Durden DL, Salazar AM, Distusio JA. Kinetic analysis of hep-atotoxicity associated with antineoplastic asparaginases. Cancer Res 1983;43:1602-1605. (Pubitemid 13122555)
81. Capizzi RL. Asparaginase-Mtx in combination chemotherapy: schedule-dependent dif erential effects on normal versus neoplastic cells. Cancer Chemother Rep 1981;65:115-121. (Pubitemid 13243417)
82. Capizzi RL, Grifn F, Cheng YC, Baily K, Rudnick SA. High dose Ara-C with asparaginase in the treatment of refractory leukemia. Proc Am Assoc Cancer Res 1980;21:148 Abstract.
83. Schwartz S, Morganstern B, Capizzi RL. Schedule-dependent synergy and antagonism between high-dose 1-β-D-arabinofuranosyl cytosine and asparaginase in the L5178Y murine leukemia. Cancer Res 1982;42:2191-2197. (Pubitemid 12121430)
84. Ladas EJ, Kroll DJ, Oberlies NH, et al. A randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hep-atotoxicity in childhood acute lymphoblastic leukemia. Cancer 2010;116:506-513.
85. Hongo T, Okada S, Ohzeki T, et al. Low plasma levels of hemostatic proteins during the induction phase in children with acute lymphoblastic leukemia: a retrospective study by the JACLS. Japan Association of Childhood Leukemia Study. Pediatr Int 2002;44: 293-299. (Pubitemid 34827730)
86. Andrew M, Brooker L, Mitchell L. Acquired antithrombin III def ciency secondary to asparaginase therapy in childhood acute lymphoblastic leukaemia. Blood Coagul Fibrinolysis 1994;5 (Suppl. 1):S24-S36;discussion S59-S64. (Pubitemid 24049883)
87. Mitchell L, Hoogendoorn H, Giles AR, Vegh P, Andrew M. Increased endogenous thrombin generation in children with acute lymphoblastic leukemia:risk of thrombotic complications in L-asparaginase-induced antithrombin III defciency. Blood 1994;83:386-391.
88. Bushman JE, Palmieri D, Whinna HC, Church FC. Insight into the mechanism of asparaginase-induced depletion of antithrombin III in treatment of childhood acute lymphoblastic leukemia. Leuk Res 2000;24:559-565.
89. Hernandez-Espinosa D, Minano A, Martinez C, et al. L-asparaginase-induced antithrombin type I def ciency: implications for conformational diseases. Am J Pathol 2006;169:142-153.
90. Hernandez-Espinosa D, Minano A, Ordonez A, et al. Dexamethasone induces a heat-stress response that ameliorates the conformational consequences on antithrombin of L-asparaginase treatment. J Tromb Haemost 2009;7:1128-1133.
91. Priest JR, Ramsay NK, Latchaw RE, et al. T rombotic and hemo-rrhagic strokes complicating early therapy for childhood acute lymphoblastic leukemia. Cancer 1980;46:1548-1554. (Pubitemid 10009359)
92. Liebman HA, Wada JK, Patch MJ, McGehee W. Depression of functional and antigenic plasma antithrombin III (AT-III) due to therapy with L-asparaginase. Cancer 1982;50:451-456. (Pubitemid 12097412)
93. Mitchell LG, Halton JM, Vegh PA, et al. effect of disease and chemotherapy on hemostasis in children with acute lymphoid leukemia. Am J Pediatr Hematol Oncol 1994;16:120-126.
94. Jonas Kimchi T, Lee SK, Agid R, Shrof M, Ter Brugge KG. Cerebral sinovenous thrombosis in children. Neuroimaging Clin N Am 2007;17:239-244. (Pubitemid 47082472)
95. Caruso V, Iacoviello L, Di Castelnuovo A, et al. T rombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood 2006;108:2216-2222. (Pubitemid 44497502)
96. Payne JH, Vora AJ. T rombosis and acute lymphoblastic leukaemia. Br J Haematol 2007;138:430-445.
97. Nowak-Gottl U, Kenet G, Mitchell LG. T rombosis in childhood acute lymphoblastic leukaemia: epidemiology, aetiology, diagnosis, prevention and treatment. Best Pract Res Clin Haematol 2009;22:103-114.
98. Kieslich M, Porto L, Lanfermann H, Jacobi G, Schwabe D, Bohles H. Cerebrovascular complications of L-asparaginase in the therapy of acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2003;25:484-487. (Pubitemid 36682755)
99. Qureshi A, Mitchell C, Richards S, Ajay Vora A, Goulden N. Asparaginase-related venous thrombosis in UKALL 2003-re-exposure to asparaginase is feasible and safe. Br J Haematol 2010;149: 410-413.
100. Grace RF, Dahlberg SE, Neuberg D, et al. Te frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol 2011;152:452-459.
101. Caruso V, Iacoviello L, Di Castelnuovo A, Storti S, Mariani G, deGaetano G, Donati MB. Trombotic complications in childhood acutelymphobl asticleukemia: ameta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood 2006;108:2216-2222. (Pubitemid 44497502)
102. Elliott MA, Wolf RC, Hook CC, et al. Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: incidence, risk factors, and possible role of antithrombin. Leuk Lymphoma 2004;45:1545-1549.
103. Hunault-Berger M, Chevallier P, Delain M, et al. Changes in antithrombin and f brinogen levels during induction chemo therapy with L-asparaginase in adult patients with acute lym phoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagu lation therapy and clinical outcome: the CAPELAL study. Haemato logica 2008;93:1488-1494.
104. Caruso V, Iacoviello L, Di Castelnuovo A, Storti S, Donati MB. Venous thrombotic complications in adults undergoing induction treatment for acute lymphoblastic leukemia: results from a meta-analysis. J Tromb Haemost 2007;5:621-623. (Pubitemid 46680704)
105. Gugliotta L, Mazzucconi MG, Leone G, et al. Incidence of thrombotic complications in adult patients with acute lym phoblastic leukaemia receiving L-asparaginase during induction therapy: a retrospective study. Te GIMEMA Group. Eur J Haematol 1992;49:63-66.
106. Abbott LS, Deevska M, Fernandez C V, et al. Te impact of prophylactic fresh-frozen plasma and cryoprecipitate on the incidence of central nervous system thrombosis and hemorrhage in children with acute lymphoblastic leukemia receiving aspa raginase. Blood 2009;114:5146-5151.
107. Appel IM, Hop WC, van Kessel-Bakvis C, Stigter R, Pieters R. L-Asparaginase and the effect of age on coagulation and f brinolysis in childhood acute lymphoblastic leukemia. T romb Haemost 2008;100:330-337.
108. Nowak-Gottl U, Ahlke E, Fleischhack G, et al. T romboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration. Blood 2003;101:2529-2533. (Pubitemid 36857608)
109. Nowak-Gottl U, Wermes C, Junker R, et al. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood 1999;93:1595-1599. (Pubitemid 29102487)
110. Mitchell LG, Andrew M, Hanna K, et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study. Cancer 2003;97:508-516. (Pubitemid 36133819)
111. Naina HV, Harris S, Patnaik MM. Treating childhood leukemia without cranial irradiation. N Engl J Med 2009;361:1310-1311; author reply 1311-1312.
112. Meister B, Kropshofer G, Klein-Franke A, Strasak AM, Hager J, Streif W. Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2008;50: 298-303.
113. Korte W, Greiner J. PARKAA paves the way. T romb Haemost 2003;90:163-164. (Pubitemid 36992492)
114. Jaing TH, Lin JL, Lin YP, Yang SH, Lin JJ, Hsia SH. Hyperam-monemic encephalopathy after induction chemotherapy for acute lympho blastic leukemia. J Pediatr Hematol Oncol 2009; 31: 955-956.
115. Miyazawa Y, Irisawa H, Matsushima T, et al. Reversible post e rior leukoencephalopathy syndrome probably caused by L-asparaginase. Rinsho Ketsueki 2006;47:531-535.
116. Rathi B, Azad RK, Vasudha N, Hissaria P, Sawlani V, Gupta RK. L asparaginase-induced reversible posterior leukoencephalopathy syndrome in a child with acute lymphoblastic leukemia. Pediatr Neurosurg 2002;37:203-205. (Pubitemid 35316916)
117. Winick NJ, Bowman WP, Kamen BA, et al. Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia. J Natl Cancer Inst 1992;84:252-256.
118. Silverman LB, Supko JG, Stevenson KE, et al. Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Blood 2010;115:1351-1353.
119. Peters BG, Goeckner BJ, Ponzillo JJ, Velasquez WS, Wilson AL. Pegaspargase versus L-asparaginase in adult ALL: a phar-macoeconomic assessment. Formulary 1995;30:388-393.
120. van den Berg H. Asparaginase revisited. Leuk Lymphoma 2011; 52:168-178.
121. Benezra D, Pitaro R, Birkenfeld U, Hochman A. Reversal of the immunosuppressive effect of l-asparaginase by l-glutamine. Nat New Biol 1972;236:80-82.
122. Uren JR, Handschumacher RE. Enzyme therapy. In: Becker FF, editor. Cancer: a comprehensive treatise, Vol. 5. New York: Plenum Publishing; 1977. p. 457-487.
123. Woods JS, Handschumacher RE. Hepatic homeostasis of plasma l-asparagine. Am J Physiol 1971;221:1785-1790.
124. Miller HK, Salser JS, Balis ME. Amino acid levels following l-asparagine amino hydrolase (EC 3.5.1.1) therapy. Cancer Res 1969;29:183-187.
125. Rytting M, T omas D, Franklin A, et al. Young adults with acute lymphoblastic leukemia (ALL) treated with adapted augmented Berlin-Frankfurt- Munster (ABFM) therapy. Blood 2008;112(Suppl. 1): Abstract 3957.